京东健康（06618）今日盘中股价表现强劲，大涨5.13%，引发市场关注。
消息面上，里昂证券（CLSA）发布研究报告，上调京东健康目标价至66港元（此前为64港元），并维持"跑赢大市"评级。里昂预期公司第三季度总收入将同比增长25%至166亿元人民币，主要受益于原厂药和慢性病药销售的强劲增长。报告指出，公司第三季度药物销售预计保持同比30%以上的稳健增长，而保健品销售增长预计超过20%。
此外，里昂上调了京东健康2025年全年收入增长预测至22%，并预计公司EBIT利润率将达到5.7%（此前预测为5.0%）。分析师还上调了公司今明两年的经调整净利润预测，分别上调5%和4%。这一系列积极的预期调整，反映了机构对京东健康未来业绩的信心，成为推动股价上涨的重要因素。
京东健康股价的强劲表现，反映了投资者对公司业务前景的乐观预期，特别是在处方药和慢性病管理等核心业务领域。随着中国医疗健康行业的持续发展和数字化转型，京东健康作为领先的在线医疗健康平台，有望继续受益于行业增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.